Finance

Beta
Lists
007570:KRX
Ilyang Pharmaceutical Co Ltd
₩8,530.00
+4.02%
(+330.00) 1D
Jun 12, 3:30:29 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 007570...
Open
₩8,270
High
₩8,750
Low
₩8,200
Mkt. cap
166.34B
Avg. vol.
84.92K
Volume
0.00
Dividend
1.82%
Quarterly dividend
₩39
Ex-dividend date
Dec 27, 2023
P/E ratio
7.40
52-wk high
₩16,240
52-wk low
₩7,770
EPS
₩1,153
Shares outstanding
19.09M
No. of employees
666
Open
₩8,270
High
₩8,750
Low
₩8,200
Mkt. cap
166.34B
Avg. vol.
84.92K
Volume
0.00
Dividend
1.82%
Quarterly dividend
₩39
Ex-dividend date
Dec 27, 2023
P/E ratio
7.40
52-wk high
₩16,240
52-wk low
₩7,770
EPS
₩1,153
Shares outstanding
19.09M
No. of employees
666
News stories
From sources across the web
About Ilyang Pharmaceutical Co Ltd
CEOKim Dong-yeon
Employees666
FoundedJul 1, 1946
Headquarters-
SectorPharmaceutical industry
Websitehome.ilyang.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
62.70B
68.83B
78.91B
65.07B
Cost of goods sold
35.93B
41.32B
45.42B
40.63B
Cost of revenue
35.93B
41.32B
45.42B
40.63B
Research and development expenses
5.94B
7.01B
7.00B
8.87B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.05B
19.76B
24.92B
22.29B
Operating expense
25.60B
27.66B
32.93B
31.82B
Total operating expenses
61.53B
68.98B
78.35B
72.44B
Operating income
1.17B
-157.75M
565.93M
-7.37B
Other non operating income
-969.70M
11.87B
-681.30M
24.70B
EBT including unusual items
192.59M
11.42B
-1.72B
17.95B
EBT excluding unusual items
179.37M
11.35B
-1.72B
17.62B
Income tax expense
-420.76M
3.04B
3.92B
983.97M
Effective tax rate
-218.48%
26.58%
-227.04%
5.48%
Other operating expenses
400.58M
639.84M
573.32M
453.35M
Net income
576.52M
8.44B
-5.65B
16.80B
Net profit margin
0.92%
12.26%
-7.16%
25.81%
Earnings per share
-
-
-
-
Interest and investment income
85.56M
-
184.97M
140.72M
Interest expense
-744.99M
-
-738.07M
-711.18M
Net interest expenses
-659.43M
-
-553.10M
-570.46M
Depreciation and amortization charges
208.06M
212.18M
210.49M
211.82M
EBITDA
3.26B
1.93B
2.65B
-5.30B
Gain or loss from assets sale
-17.86M
-71.72M
6.86K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer